Anupam Rasayan scores a global first in ETFA production
The company claims a world-first commercialisation of Ethyl trifluoroacetate via continuous flow chemistry, with an addressable market of **$500–600M** but no revenue number yet.
— 1 earlier story on Anupam Rasayan India Ltd. →What's new
- Anupam Rasayan has commercially produced Ethyl trifluoroacetate (ETFA) using continuous flow chemistry, a global first.
- ETFA is a fluorinated building block for pharma, life sciences, and performance materials.
- The company's process-by-design platform claims safety and scalability advantages over batch processes.
Why this matters
This is a genuine technological differentiator in fluorinated chemicals. Yet with trailing PAT down 11% and EBITDA margin guidance cut 200 bps to 23-24% just weeks ago, the financial translation matters. The addressable market is large but unquantified in revenue terms.
What we're watching
- Any offtake agreements or pilot orders for ETFA.
- Revenue contribution in the next 2-3 quarters.
- Capacity utilisation and pricing disclosures for the new product.
The full read
Anupam Rasayan has become the first to commercially produce Ethyl trifluoroacetate via continuous flow chemistry, a genuine technological differentiator. The addressable market is $500–600 million, but the press release carries no revenue guidance or order value. That uncertainty matters. Trailing PAT fell 11%, and the company just trimmed EBITDA margin guidance by 200 bps to 23-24%. The innovation is real. Proof will come in orders.
Questions answered
- What is ETFA and why is it significant?
- Ethyl trifluoroacetate (ETFA) is a fluorinated building block used in pharmaceuticals, agrochemicals, and performance materials. Anupam's continuous-flow process is a global first, potentially offering cost, safety, and scalability advantages over traditional batch methods.
- How big is the market opportunity for ETFA?
- The company estimates the global addressable market at $500–600 million. No regional or segment breakdown has been provided.
- Will this immediately boost Anupam's financials?
- Not immediately, as no revenue guidance or order value was disclosed. With a market cap of ₹14,322 cr and trailing P/E of 84.2, the stock already prices in growth. The recent EBITDA margin guidance cut and PAT decline add caution.
- How does this compare to recent financial performance?
- The innovation is a positive development, but Anupam just cut EBITDA margin guidance by 200 bps to 23-24% and reported trailing PAT down 11%. The market will need to see actual revenue from ETFA before reassessing.
Anupam Rasayan India Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ANURAS →- 11 Jun 2026 · 7:59 PM IST Anupam Rasayan scores a global first in ETFA production
- 42d ago Anupam Rasayan cuts EBITDA margin guidance by 200 bps, flags consolidation drag